Prime Medicine, Inc. (PRME)

In the past six months, Prime Medicine's stock has experienced fluctuations, including a 27.62% increase from October 2024 to October 2025, as well as declines in mid-October 2025. Analyst ratings have been mixed, with downgrades and upgrades, but the stock received a "Moderate Buy" consensus rating with an average one-year target price of $8.92. Positive news, such as a bullish report from JonesTrading and insider activity, has also impacted the stock, along with the announcement of positive initial clinical data for PM359.

There is no specific information indicating demand seasonality for Prime Medicine, Inc.'s products and services, as demand is primarily driven by the prevalence of targeted genetic disorders and progress through clinical trials and regulatory approvals.

Prime Medicine, Inc. is a biotechnology company focused on developing one-time curative genetic therapies using its Prime Editing technology, which acts as a DNA word processor to precisely "search and replace" disease-causing genetic sequences. The company is advancing a diversified portfolio of investigational therapeutic programs across hematology, immunology & oncology, liver, and lung, including PM359 for Chronic Granulomatous Disease (CGD), and has research collaborations with Cimeio Therapeutics and Bristol Myers Squibb.

Prime Medicine, Inc. is headquartered in Cambridge, Massachusetts, United States, with its operations and focus primarily within the United States.

Prime Medicine's brand reputation has been mixed, with a leaning towards a "Moderate Buy" consensus. While some analysts have maintained a "sell" rating, others have adjusted their ratings. A bullish report from JonesTrading and positive initial clinical data for PM359 have positively impacted its perception, as have collaborations with strategic partners like Bristol Myers Squibb and the Cystic Fibrosis Foundation.

The ownership structure of Prime Medicine, Inc. includes institutional investors (70.37%), insiders (22.7%), and retail investors (30%). Major institutional owners include Alphabet Inc., T. Rowe Price Investment Management, Inc., and ARK Genomic Revolution ETF (ARKG). The largest individual shareholder is David R. Liu, who holds 12% of the shares outstanding.